FindTrial
Sign In

An exploratory clinical trial for optimizing vancomycin therapy in Korean patients with MRSA infection

An exploratory clinical trial to evaluate the clinical benefit of AUC-based vancomycin TDM in Korean patients with MRSA infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006018
Enrollment
80
Registered
2021-03-24
Start date
2021-03-22
Completion date
Unknown
Last updated
2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kangwon National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Patients who have the ability to sign the consent form in accordance with GCP and corresponding laws ? Patients who are 19 years or older ? Patients who were decided to administer vancomycin for 7 days or more due to MRSA infection or within 3 days after initiation of vancomycin dosing ? Patient who understands the contents of the clinical research and provide their written informed consent forms

Exclusion criteria

Exclusion criteria: ? Patients who co-administered vancomycin, except for the intravenous route. (e.g., per oral) ? Patients with contraindications for vancomycin (e.g., Anaphylaxis due to vancomycin) ? Patients in pregnancy or lactation ? Patients whom the researcher deemed inappropriate for clinical research participation

Design outcomes

Primary

MeasureTime frame
Pharmacokinetic parameters (AUC, Ctrough)—

Secondary

MeasureTime frame
Occurrence of nephrotoxicity—

Countries

Korea, Republic of

Contacts

Public ContactSang-In Park

Kangwon National University

sibach27@gmail.com+82-33-250-8851

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026